NumerixS Investment Technologies Inc Has $1.63 Million Holdings in Amgen, Inc. (AMGN)
NumerixS Investment Technologies Inc decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,910 shares of the medical research company’s stock after selling 779 shares during the period. NumerixS Investment Technologies Inc’s holdings in Amgen were worth $1,634,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently bought and sold shares of AMGN. LSV Asset Management lifted its stake in Amgen by 3.2% in the second quarter. LSV Asset Management now owns 4,157,649 shares of the medical research company’s stock worth $767,460,000 after acquiring an additional 128,865 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in Amgen by 2.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock worth $592,025,000 after acquiring an additional 72,205 shares during the period. Dimensional Fund Advisors LP lifted its stake in Amgen by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock worth $436,551,000 after acquiring an additional 343,690 shares during the period. Aristotle Capital Management LLC lifted its stake in Amgen by 3.9% in the first quarter. Aristotle Capital Management LLC now owns 2,279,468 shares of the medical research company’s stock worth $388,604,000 after acquiring an additional 86,378 shares during the period. Finally, Swiss National Bank lifted its stake in Amgen by 3.2% in the second quarter. Swiss National Bank now owns 2,227,926 shares of the medical research company’s stock worth $411,253,000 after acquiring an additional 69,500 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.
AMGN has been the subject of a number of research reports. TheStreet raised shares of Amgen from a “c+” rating to a “b-” rating in a research note on Friday, May 25th. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 19th. Mizuho set a $200.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research note on Tuesday, May 15th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research note on Monday, July 16th. Finally, Morgan Stanley upped their price objective on shares of Amgen from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, July 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $202.76.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.52 by $0.31. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 10.19% and a return on equity of 43.18%. Amgen’s revenue was up 4.3% on a year-over-year basis. During the same period last year, the firm posted $3.27 EPS. analysts predict that Amgen, Inc. will post 13.95 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 7th. Investors of record on Friday, August 17th will be given a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend is Thursday, August 16th. Amgen’s payout ratio is currently 41.97%.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $195.71, for a total value of $298,457.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.19% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Article: Should You Consider an Index Fund?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.